Design and synthesis of benzo[b]thiophene‐based hybrids as novel antitubercular agents against MDR/XDR Mycobacterium tuberculosis

Abstract

AbstractIn an effort to support the global fight against tuberculosis (TB), which is widely recognized as the most lethal infectious disease worldwide, we present the design and synthesis of new benzo[b]thiophene‐based hybrids as promising candidates for the management of multidrug‐resistant (MDR)/extensively drug‐resistant (XDR) Mycobacterium tuberculosis. The isatin motif was incorporated into the target hybrids as it represents a privileged scaffold in antitubercular drug discovery. Since lipophilicity plays a pivotal role in the anti‐TB agents' activity, the lipophilicity of the target hybrids was manipulated via the development of two series of N‐1 methyl and N‐1 benzyl substituted isatins (6a–h and 9a–h, respectively). Screening of the target hybrids was first performed against drug‐sensitive M. tuberculosis (ATCC 25177). The structure–activity relationship outputs highlighted that incorporation of 3‐unsubstituted benzo[b]thiophene and 5‐methoxy isatin moieties was favorable for the antimycobacterial activity. Thereafter, the most potent molecules (6b–h, 9c–e, and 9h) were evaluated against the resistant strains MDR‐TB (ATCC 35822) as well as against XDR‐TB (RCMB 2674) where they displayed promising activity. To evaluate the safety of the target hybrids, an sulforhodamine B assay was conducted to determine their possible cytotoxic effects on VERO cells.